background: Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of ovarian stimulation associated with severe vascular hyperpermeability. Primary co-cultures of human luteinized granulosa cells (LGCs) and human umbilical vein endothelial cells (HUVECs) were used as a model of steroidgenic/endothelial cell interaction in OHSS.
Introduction
The developing human corpus luteum incorporates a tightly regulated system of cellular communication between luteal steroidogenic cells and endothelial cells. This facilitates the marked neovascularization associated with luteal formation and the rapid release of large quantities of progesterone into the bloodstream . Integral to these processes is the regulation of endothelial proliferation and vessel permeability by LH and hCG. While this is of fundamental physiological importance in human fertility, and ovarian function, it is also implicated in the development of ovarian hyperstimulation syndrome (OHSS).
OHSS is a life-threatening iatrogenic condition associated with assisted reproduction (Delvigne and Rozenberg, 2003) . It is a systemic disease resulting from vasoactive products released from hyperstimulated ovaries. It is characterized by increased capillary permeability leading to leakage of fluid from the vascular compartment. As many as 33% of IVF cycles have been reported to be associated with mild forms of OHSS and 3-8% of cycles are complicated by moderate to severe OHSS (Delvigne and Rozenberg, 2002) . The molecular † The first two authors contributed equally to this work. mechanisms involved in the increased endothelial permeability are not clear but circulating vascular endothelial growth factor (VEGF) is thought to play a major role in its development (Wang et al., 2002) .
The regulation of paracellular permeability involves cell-cell adhesion complexes (Bazzoni and Dejana, 2004) . Tight junctions form the most apical component of these intercellular junctional complexes and are composed of at least three different families of transmembrane proteins. Some of those are more tissue-specific, such as claudin 5 that is preferentially localized to the endothelium. Tight junctions seal the barrier between the luminal compartment and the tissue compartment. Thus, in tissues in which the tissue function depends on a tight blood/tissue barrier, such as the brain, endothelial tight junctions are highly expressed (Risau et al., 1998; Harhaj and Antonetti, 2004) . In the brain, decreased number of tight junction proteins, especially claudin 5, has been shown to be associated with increased vascular permeability (Harhaj and Antonetti, 2004; Wen et al., 2004) .
Recently, we demonstrated claudin 5 expression in the vasculature of the human corpus luteum that was decreased after in vivo treatment with hCG (Groten et al., 2006) . This effect may be secondary to VEGF as hCG induces its expression in luteal cells in vitro (Neulen et al., 1995 (Neulen et al., , 1998 and in vivo (Wulff et al., 2000) . Indeed, VEGF has been shown to enhance vascular permeability (Dvorak et al., 1999; Dvorak, 2002) and influence endothelial adherens junctions (Esser et al., 1998a) . In addition, we have shown, in the non-human primate, that blockade of VEGF in vivo during the mid-luteal phase led to a rapid decline in serum progesterone strongly suggesting a decrease in endothelial permeability, and this treatment has now been shown to increase claudin 5 protein expression in the corpus luteum (Rodewald et al., 2007) .
If hCG mediates changes in luteal endothelial cell permeability through VEGF-induced down-regulation of claudin 5, we hypothesized that this process may be fundamental to the pathogenesis of OHSS. We therefore aimed to assess the effect of luteal cell products on nonluteal endothelial cell function. We therefore established an in vitro co-culture model of luteinized granulosa cells (LGCs) and human umbilical vein endothelial cells (HUVECs). A two-chamber system was established, separating the two cell types by a micropore membrane. Using this model, we studied the effects of hCG on endothelial cell permeability and claudin 5 expression in the presence or absence of the VEGF inhibitor Flt-1Fc.
Materials and Methods

Primary cell isolation and culture
The collection of human primary cells was institutionally approved after favorable ethical review and written consent of the patients.
Endothelial cells
Human umbilical cords were rinsed with water and disinfected with isoseptol. Under sterile conditions, the ends of the cords were cut and into each end, a flexible tube was inserted and fixed with a cable tie. The umbilical veins were rinsed with phosphate-buffered saline (PBS). One end was clamped and from the other end, the vein was filled with type 1 collagenase (1 mg/ml; Sigma-Aldrich, Steinheim, Germany) to detach the endothelial cells. Subsequently, the second end was clamped and the cords were incubated in a water bath at 378C for 15 min.
HUVECs were collected and mixed 1:1 with endothelial cell growth medium (Promocell C-22010, Heidelberg, Germany) þ 10% fetal calf serum (FCS) with 1% penicillin/streptomycin (PAA, Austria). After centrifugation for 5 min at 300g the supernatant was discarded and the pellet was resuspended in culture medium. The HUVECs were seeded either in 6-well plates or tissue flasks (25 cm   2 ) and incubated at 378C in 5% CO 2 .
Luteinized granulosa cells
LGCs were extracted from follicular fluid obtained at oocyte collection from women undergoing IVF after ovarian stimulation using a standard protocol . Seven milliliters F12-Dulbecco's modified Eagle's medium (DMEM) medium (PAA, Austria) containing 10% FCS with penicillin/streptomycin and fungizone (Promocell, Heidelberg, Germany) were mixed with 6 ml follicular fluid. After centrifugation (3 min; 140g), the supernatant was discarded and the pellet resuspended in cell culture medium and further centrifuged. The cells were pooled, resuspended in 4 ml filter-sterilized lysis buffer (4.15 g NH 4 CL þ 0.5 g KHCO 3 þ 18.5 mg EDTA in 500 ml H 2 O) with 4 ml culture medium and 10% FCS, and centrifuged. This was carried out once or twice until there was no erythrocyte contamination. The cells were then seeded in cell culture medium in 6 cm tissue dishes (Sarstedt, Newton, USA). The next day, the cells were rinsed and the medium was renewed.
Co-culture of HUVEC and LGC
HUVECs (1 Â 10 6 ) were seeded onto coverslips, transferred to 6-well plates and grown to 90 -100% confluency. On the second day of culture, LGCs were either transferred to cell culture inserts (0.4 mm pore size, Becton Dickinson Nr. 353090) or frozen in F12-DMEM containing 10% dimethylsulfoxide for later use. Cell culture inserts with LGCs were inserted into the 6-well plates with HUVECs in culture (Fig. 1a) . In this setting, molecules secreted by LGCs follow the concentration gradient between the two different media such that the HUVECs can be stimulated.
Testing the membrane permeability
The LGCs were seeded on the micropore membrane. To reach adherence, they were cultured overnight at 378C in 5% CO 2 . The next day the culture medium was renewed and the system stimulated with hCG (1000 IU/ml) (Ferring, Germany) for 8, 24 and 48 h. No HUVECs were seeded in order to prevent the uptake or metabolism of VEGF in the lower well. Quantification of the VEGF concentration on both sides of the membrane was performed by enzyme-linked immunosorbent assay (ELISA).
Quantification of VEGF by ELISA
Quantitative VEGF immunoassay was performed according to the manufacturer's protocol (R&D Systems, Minneapolis, USA). Briefly, 50 ml assay diluent was added to 200 ml of control, sample or standard. After 2 h incubation at room temperature, the samples were washed three times. Then 200 ml VEGF conjugate was added for 2 h and the samples were washed again. After incubation with 200 ml substrate solution for 20 min, 50 ml stop solution was added and the optical density was measured at 450 nm.
Treatment protocols
All treatments were carried out on at least three to six separate occasions with pooled cells. HUVECs cultured alone were stimulated with carrier solution as controls, with hCG (1000 IU/ml) or with the VEGF inhibitor Flt-1Fc (100 ng/ml) (Sigma Aldrich, MO, USA) for 48 h. The VEGF inhibitor is a soluble chimeric protein which contains a truncated form of the VEGF-binding domain of the Flt receptor fused to the Fc arm of human immunoglobulin G. Furthermore, HUVEC mono-cultures were treated with 100 and 500 ng VEGF (Sigma Aldrich) for 48 h. Control incubations with carrier solutions were used for both experiments. Effects on claudin 5 membrane protein expression were quantified by western blotting.
In the co-culture experiments: (i)
LGCs were stimulated with hCG (500 IU/ml) for 48 h by adding hCG to the upper LGC compartment; (ii) the same hCG-stimulation of LGCs was performed in the presence of the VEGF inhibitor Flt-1Fc (100 ng/ml) in the HUVEC compartment (Fig. 1a) ; (iii) HUVECs were incubated with Flt-1Fc (100 ng/ml) in the absence of hCG stimulation and (iv) control incubations with carrier solutions were used in both layers.
Permeability assay for the LGC/HUVEC co-culture
To test the permeability of endothelial cells for macromolecules, the HUVECs were seeded in the insert with the LGCs underneath (Fig. 1b) to allow the flow of the dye through the membrane. HUVECs were seeded on micropore inserts (pore size 0.4 mm) at a density of 3 Â 10 5 cells per insert and cultured for 4 days. On the second day, LGCs were seeded into 6 wells and cultured in medium for 2 days. The inserts were then moved into the wells containing the LGCs (Fig. 1b) . In this co-culture system, LGCs were stimulated with hCG (1000 IU/ml) or/ and Flt-1Fc (100 ng/ml) administration to the HUVEC compartment for another 48 h. The co-culture was then washed with PBS to remove the stimulation medium.
Bovine serum albumin (BSA) was labeled with Trypan Blue (200 mg Trypan Blue to 4.8 g BSA), mixed with culture medium 1:1, and added to the insert, whereas unlabeled albumin was added to the lower compartment. Samples of the upper and lower wells were taken after 10, 20 and 30 min and protein concentration was measured at 607 nm. Each experiment was repeated on three to six separate occasions.
Permeability assay for the HUVEC monoculture
To measure endothelial permeability after claudin 5 knock down (see below) in HUVECs, the same conditions as described above were used, except that no LGCs were added to the lower chamber.
Immunocytochemistry
The coverslips with HUVECs from the co-culture were fixed with methanol. Batch immunofluorescence was carried out using a commercial kit (TSA Kit; Perkin Elmer, Boston, MA, USA) according to the manufacturer's protocol. Briefly, after blocking at room temperature for 30 min, the primary antibody (a-claudin 5 antibody; Zymed, Carlsbad, CA, USA) was added at a dilution of 1:100 and incubated overnight at 48C. After washing, the secondary antibody (biotinylated rabbit-anti-mouse, DAKO, Denmark), diluted 1:300, was added for 45 min and the coverslips were washed again. Streptavidin horseradish peroxidase diluted 1:100 was then added for 30 min. After repeat washing, Fluorescein-Tyramid (1:100; TSA Kit) was applied for 7 min. After further washes, the nuclear counterstain 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA) was added. Coverslips were placed onto slides and mounted using Vectashield w (Vector Laboratories).
Image analyses
Quantitative analysis of immunostaining was performed in randomly chosen high-power fields (n ¼ 5 per group). Cells which were positive for claudin 5 were counted and expressed as a percentage of the total number of cells (150-200 cells per high power field) identified by counting the DAPI-stained nuclei. Values were expressed as mean + SEM for all analyzed fields per slide.
Extraction of membrane protein
To obtain membrane fractions, cells were harvested into PBS. After centrifugation (5 min, 300g), the pellet was resuspended in 200 ml detergentfree lysis buffer [20 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 10 mM b-mercaptoethanol, proteinase-and phosphatase-inhibitor cocktail (Sigma)]. Cells were disrupted in a glass dounce homogenizer, incubated on ice, and ultracentrifuged at 100 000g for 45 min at 48C. The supernatant was referred to as the cytosolic fraction. The remaining pellet was resuspended in lysis buffer [Tris-buffered saline pH 7.6, containing a proteinaseand phosphatase-inhibitor cocktail and 0.5% Triton X-100 (Amresco, Solon, OH, USA)]. Lysates were centrifuged at 20 000g for 10 min and the supernatant was reserved as the membrane fraction. Protein concentration was determined using the BCA Protein Assay (Pierce, Rockford, IL, USA).
Western blotting
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis in 4 -20% Tris -glycine gels (Lonza, Rockland, USA) and transferred onto 0.45 mm nitrocellulose membranes (Schleicher Schuell, Dassel, Germany). After blocking with 5% milk, the membranes were incubated with the primary antibody at 48C overnight [a-claudin 5 Figure 1 Cartoon illustrating the co-culture paradigm.
(a) For assessment of the effects on HUVECs at a molecular level, HUVECS were cultured on the bottom of the well with LGCs added to the insert; (b) for assessment of HUVEC permeability, the HUVECs were cultured on the insert with LGCs grown on the bottom of the well. Treatments involved the addition of hCG (1000 IU/ml) and the VEGF inhibitor Flt-1Fc (10 ng/ml) to the cell layers.
antibody at 1:1000 dilution or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody at 1:500 dilution]. Detection involved incubation with peroxidase-conjugated secondary antibody (sheep-anti mouse, GE Healthcare UK Limited, Little Chalfont Buckinghamshire, UK) at room temperature for 1 h. After washing, protein -antibody complexes were visualized by enhanced chemiluminescence (ECL) using the ECL Western Blot Detection Reagents (GE Healthcare UK Limited). Optical density of the bands was quantified (Imager of Alpha Corporation, San Leandro, CA, USA) and the results obtained for claudin 5 were normalized to the values for GAPDH, which is constitutively expressed in HUVECs.
Small interfering RNA knock down
One day before transfection, 8 Â 10 5 cells were seeded into cell culture flasks and cultured under normal growth conditions (378C; 5% CO 2 ). Cells were then washed with PBS and 2 ml growth medium added. The transfection reagent contains (per T25 flask) 400 ml culture medium without serum, 6 ml small interfering RNA (siRNA) of negative control (Qiagen 1027281 20 nmol) or claudin 5 (mixture of Claudin 5_2 siRNA Qiagen SI00050190, Claudin 5_6 siRNA SI03193477 and Claudin 5_7 siRNA Qiagen SI04217591, each 5 nmol), and 12 ml HiPerFect (the transfection reagent). The transfection medium was incubated at least for 5 min in order to allow the formation of transfection complexes. HUVECs were incubated under their normal growth conditions followed by incubation with the transfection complexes. After 72, 96 and 144 h, RNA and protein was isolated for confirmation of a successful gene knock down. The permeability assay was performed for the same time points.
RNA isolation
Total RNA from HUVECs was extracted from cells with the RNeasy Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The RNA product was quantified by absorbance at 260 nm and total RNA (2.5 mg) was reverse transcribed into complementary DNA (cDNA) using random hexamer primers (Applied Biosystems, Foster City, USA).
TaqMan analysis
After the knock down of claudin 5, its suppression was quantified by TaqMan analysis using components from Applied Biosystems (Darmstadt, Germany). The PCR mixture contains 46.88 ml TaqMan Mastermix solution (4304437), 4.69 ml human 18S RNA (4319413), 4.69 ml claudin 5 (HS 01561351m1) and 3.75 ml of a 1:10 dilution of the reverse transcribed RNA as template. Amplification and detection of specific products was performed with the ABI Prism 7700 sequence detection system (PE Applied Biosystems). The quantity of cDNA for claudin 5 was normalized to the quantity of 18S RNA in each sample by dividing the fluorescence values of claudin 5 amplification by those of 18S RNA.
Statistics
Separate one-way analysis of variance tests were carried out for each set of data with Duncan's multiple range post hoc testing. For immunocytochemical quantification, Kruskal-Wallis testing with Dunn's comparisons was carried out. Analysis was performed using the Statistical Package for the Social Sciences for Windows Version 6.0 and P , 0.05 was taken as the level of significance.
Results
LGCs increase endothelial cell permeability
The permeability of a HUVEC monolayer to labeled BSA was investigated in the presence of human LGCs. Permeability tended to increase in co-cultures with LGCs and this reached significance (P , 0.05) in the presence of hCG (Fig. 2) . Secreted factors from LGCs can therefore influence endothelial cell permeability in this model system.
HCG-stimulated VEGF enters the endothelial cell compartment
As VEGF is likely to be a major hCG-stimulated regulator of vascular permeability in OHSS, VEGF concentrations were measured in both compartments of the culture system. Administration of hCG to the LGC compartment resulted in a time-dependent increase in VEGF concentrations in the upper (P , 0.05) as well as lower compartment (P , 0.05) (Fig. 3) . Baseline concentrations of VEGF did not change with time in the absence of hCG. Approximately one-third of the VEGF from the upper compartment entered the lower endothelial cell compartment.
Inhibition of VEGF action prevents the increase in permeability
Addition of VEGF inhibitor (Flt-1Fc) to the HUVEC cell compartment had no effects on monolayer permeability (Fig. 2) . However, Flt-1Fc prevented the increased permeability seen in the presence of LGCs and hCG (P , 0.05) (Fig. 2) . This suggests that, in this model system, VEGF from LGCs is involved in the paracrine regulation of endothelial cell permeability.
Paracrine regulation of claudin 5 is associated with changes in permeability
Claudin 5 protein could be localized to the plasma membrane of HUVEC monolayers in culture (Fig. 4a) . Expression of HUVEC membrane claudin 5 protein was reduced in the presence of
LGCs stimulated with hCG (Fig. 4b) . The inhibition of secreted VEGF using Flt-1Fc prevented the LGC/hCG induced down- Figure 2 Permeability of HUVEC monolayer to labeled BSA.
HUVECs on the insert were cultured in the presence or absence of
LGCs in the well, and were treated with hCG (500 IU/ml) and/or Flt-1Fc (10 ng/ml) (n ¼ 3 separate experiments).
The bars represent mean + SEM. Different letters represent significant differences at the P , 0.05 level by analysis of variance (ANOVA).
regulation of membrane claudin 5 (Fig. 4c) . Quantitative analysis revealed a significant decrease in the proportion of cells exhibiting claudin 5 immunostaining in the plasma membrane after stimulation of the co-cultured LGCs with hCG (P , 0.05) (Fig. 4d) . Although Flt-1Fc had no direct effect on HUVEC claudin 5 immunostaining, it reversed the effect of hCG in the presence LGCs (P , 0.05) (Fig. 4d) . Western blotting confirmed that hCG had no direct effect on HUVEC cell membrane claudin 5 (Fig. 5a and b) . Expression of HUVEC membrane claudin 5 protein was reduced in the presence of LGCs stimulated with hCG (P , 0.05) (Fig. 5c and d) . The inhibition of secreted VEGF using Flt-1Fc prevented the LGC/hCG induced down-regulation of membrane claudin 5 expression (P , 0.05) (Fig. 5c and d) . This confirms the paracrine regulation of endothelial claudin 5 by hCG.
VEGF-dependent expression of claudin 5 in HUVEC
Western blotting confirmed a VEGF-dependent regulation of claudin 5 protein in HUVEC monocultures. Quantification of claudin 5 after stimulation with 100 or 500 ng VEGF revealed a significant downregulation of claudin 5 (P , 0.05) (Fig. 6a and b) .
Knock down of claudin 5 increases permeability of HUVECs
In order to exclude a non-causal association of VEGF-dependent increased permeability and decreased claudin 5, we performed claudin 5 knock down (Fig. 6c) and quantified the permeability after claudin 5 knock down (Fig. 6d versus 1/Dct knock down 0.09 + 0.001, P , 0.05; for 144 h: 1/Dct control 0.12 + 0.001 versus 1/Dct knock down 0.09 + 0.0009; P , 0.05). Furthermore, western blots revealed a significant knock down after 72, 96 and 144 h (P , 0.05) (Fig. 6c) . As anticipated, we observed a time-dependent significant increase of permeability (P , 0.05) (Fig. 6d) when compared with the control.
Discussion
Although OHSS is a serious and life-threatening condition, we do not yet fully understand its molecular pathophysiology. Advances have been made in the development of animal models for OHSS (Ohba et al., 2003) , but these remain suboptimal in nature. Recent advances have been made using endothelial cell monolayers as models for endothelial cell function (Albert et al., 2002; Villasante et al., 2007) . In order to investigate the molecular regulation of endothelial cells in OHSS, we have developed an in vitro human cell co-culture model. We have demonstrated for the first time that the LGC -HUVEC co-culture system is a suitable model for studying the effects of stimulatory agents on both cell types and the molecular interactions between those cells. In addition, we have used specific inhibitors to allow us to discriminate between direct and indirect effects of the stimuli. It is likely that this novel paradigm of luteal/endothelial interaction will facilitate further dissection of the molecular regulation of OHSS.
In order to investigate this model, we focused on endothelial claudin 5 expression. We have previously shown that luteal endothelial claudin 5 was decreased in the presence of hCG during simulated maternal recognition of pregnancy (Groten et al., 2006) . As LH/hCG receptors are primarily localized to the steroidogenic cells (Duncan et al., 1996) , we hypothesized that this effect was indirectly mediated by steroidogenic cell factors. We have now been able to confirm the paracrine effect of hCG on endothelial claudin 5 using LGC/HUVEC co-cultures. In addition, we have shown that hCG treatment of
LGCs is associated with increased endothelial permeability. This suggests that luteal rescue with hCG in very early pregnancy is associated with increased vascular permeability.
There has been some debate about whether endothelial cells can be directly influenced by hCG, as LH/hCG receptors have been reported in some endothelial cells (Lei et al., 1992; Rao et al., 1993; Albert et al., 2002) . Recently, a model of OHSS, using HUVEC monocultures, suggested that hCG may have a direct effect on endothelial permeability and vascular endothelial (VE)-cadherin expression (Villasante et al., 2007) . The role, and signal transduction, of a putative endothelial cell LH/hCG receptor, however, is not yet clear. It has been suggested that the receptor has a hormone transcytosis function, to facilitate gonadotrophin delivery through the endothelium to the target cell (Misrahi et al., 1996) . Although there may be some direct effect on HUVEC function (Villasante et al., 2007) , it is clear that the principal effect of hCG on endothelial permeability and claudin 5 expression in our system was indirect, as it only occurred in the presence of LGCs.
For hCG to have this effect on endothelial cell permeability, it must regulate factors secreted from LGCs that act on endothelial cells. We provide evidence that one of the molecules transducing the hCG signal to the endothelial cells is VEGF. VEGF receptors are found on luteal endothelial cells , LGCs, and treated with hCG (1000 IU/ml) and/or Flt-1Fc (100 ng/ml). The bars represent mean + SEM. Different letters represent significant differences at the P , 0.05 level (ANOVA).
other micro-VE cells (Albert et al., 2002) and HUVECs (Villasante et al., 2007) . Indeed in this co-culture model system, hCG stimulation of LGCs increased VEGF as has previously been shown by ourselves and other investigators (Neulen et al., 1998; . In addition, hCG has been shown to stimulate VEGF expression in human luteal steroidogenic cells in vivo (Wulff et al., 2000) . As VEGF could permeate the micropore membrane to reach the endothelial cells, it has the facility to act directly on the neighboring endothelial cells.
The regulatory function of VEGF on endothelial cell permeability has previously been shown in cell culture experiments (Albert et al., 2002; Villasante et al., 2007) . It is likely that this is mediated through regulation of adhesion proteins (Esser et al., 1998b; Wright et al., 2002; Lampugnani et al., 2006) . Indeed, VEGF increased VE-cadherin release in HUVECs and this was associated with increased permeability. In vivo, VEGF caused increased vascular fenestration and leakiness, as well as angiogenesis, in rodent muscle cells (Zacchigna et al., 2007) . VEGF is therefore a strong candidate for the paracrine effects on endothelial cell permeability.
It is likely that it is the acute regulation of claudin 5 in endothelial cells that is directly associated with permeability changes. In our model, the effect on permeability seems less dramatic than that on claudin 5 localization. We demonstrated a VEGF concentrationdependent decrease of claudin 5 in the HUVEC monoculture. Furthermore, claudin 5 knock down in the HUVEC monoculture was associated with a time-dependent increase in permeability. In the co-culture model, we demonstrated the hCG-dependent decrease of claudin 5 protein in endothelial cells by both quantitative immunocytochemistry and western blotting. This was associated with changes in permeability. When VEGF action was inhibited, not only were the permeability changes inhibited but the down-regulation of claudin 5 was also prevented. It has been shown that the reduction of claudin 5 leads to a decrease in the transendothelial electrical resistance, suggesting increased permeability (Koto et al., 2007) . Indeed we Figure 6 Western blot of membrane claudin 5 and GAPDH in HUVECs.
(a) Representative western blot from HUVECs after stimulation with 100 or 500 ng VEGF (C, control); (b) quantification of claudin 5 in HUVECs after stimulation with 100 or 500 ng VEGF (C, control); different letters represent significant differences at the P , 0.05 level (ANOVA) (n ¼ 3 separate experiments); (c) representative western blot after knock down of claudin 5 (using siRNA) for 72, 96 and 144 h (C, control; KD, knock down) (n ¼ 6 separate experiments); (d) corresponding relative permeability of HUVECs after knock down of claudin 5 for 72, 96 and 144 h; different letters represent significant differences at the P , 0.05 level (ANOVA) (n ¼ 6 separate experiments).
have shown, in the non-human primate luteal vasculature, that VEGF inhibition in vivo is followed by increased claudin 5 protein expression in the corpus luteum (Rodewald et al., 2007) . In addition, in a rat model of OHSS, treatment with hCG down-regulated ovarian claudin 5 expression (Kitajima et al., 2006) .
It is likely, however, that other molecules are involved in the regulation of endothelial permeability in addition to claudin 5. VE-cadherin is involved in angiogenesis and endothelial cell function (Nakhuda et al., 2005) and it is altered in VEGF-induced changes in HUVEC monolayer permeability (Villasante et al., 2007) . We have also shown that VE-cadherin, as well as occludin and claudin 1, is inhibited by hCG in human corpus luteum in vivo (Groten et al., 2006) . It is also possible that VEGF is not the only luteal molecule involved in regulation of permeability and claudin 5 expression. In the follicular fluid, several angiogenic factors have been identified which may have agonistic or antagonistic effects (Gruemmer et al., 2005a, b) . It may be hypothesized that LGCs synthesize different factors which act synergistically on endothelial adhesion proteins.
It is likely that these observations inform us about the important features of the molecular pathophysiology of OHSS (Albert et al., 2002; Kitajima et al., 2006; Villasante et al., 2007) as well as other pathological conditions associated with increased vascular permeability (Karmpaliotis et al., 2002; Kosmidou et al., 2007) . With regard to OHSS, the current strategies for prevention involve withholding hCG in women at risk to prevent ovulation and luteal formation (Mathur et al., 2007) . Once OHSS has developed, its management involves supportive measures including rehydration and antithrombotic drugs (Delvigne and Rozenberg, 2003; Mathur et al., 2007) . As VEGF is likely to have a major role in the etiology of OHSS, one novel therapeutic strategy is to target VEGF action (Soares et al., 2008) . Indeed, OHSS is associated with increased circulating VEGF concentrations (Levin et al., 1998) and it is likely that inhibiting VEGF will offer increased therapeutic options.
Another potential management option would be the direct targeting of endothelial cell adhesion proteins such as claudin 5. It has been shown that soluble VE-cadherin concentrations correlate with the severity of OHSS (Villasante et al., 2008) and that inhibition of the VE cadherin system using antibodies can inhibit angiogenesis, and possibly vascular permeability, in the rat ovary (Nakhuda et al., 2005) . Further work, therefore, needs to be done on the pharmacological manipulation of tight junctional protein complexes in endothelial cells.
In summary, the potential of VEGF to enhance vascular permeability is well known (Dvorak, 2002) and an involvement of cell adhesion proteins in this process has been suggested (Harhaj et al., 2006; Koto et al., 2007) . However, here we have shown for the first time, using a novel LGC -HUVEC co-culture system, a direct link between hCG, VEGF, claudin 5 and endothelial permeability. The paracrine effect of hCG that down-regulates endothelial membrane-bound claudin 5 adhesion protein is associated with an increase in endothelial permeability. This has implications for the pathogenesis and future management and monitoring strategies for OHSS.
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